Literature DB >> 23025789

Validation of cord blood split products prepared by an automated method.

K Gutensohn1, M Odendahl, J F Kersten, T Tonn.   

Abstract

OBJECTIVES: In this study, we studied whether the contents of the two compartments of automatically processed cord blood (CB) units are comparable with respect to cell counts and viability and therefore suitable for clinical therapy.
BACKGROUND: CB-derived stem cells are increasingly used for allogeneic transplantation. Many centres prepare the transplants by automated methods allowing to split the product into two portions.
METHODS: CB was collected at different sites in Germany and transported to a single centre for processing. Before and after cryopreservation laboratory analyses were performed to compare the quality of the two CB segments.
RESULTS: In total, 33 products were processed [mean collection volume: 18·6 ± 1·2 mL (range 15·2-20·2 mL) segment A; mean: 4·7 ± 0·3 mL (range 4·2-5·2 mL) segment B]. CD34+ cell counts, viability of CD34+ cells and many other haematological parameters showed a good comparibility between the two segments. However, lymphocyte counts and results of clonogenic assays were significantly different between the two segments of the split product.
CONCLUSION: We conclude that the preparation of the cord blood unit by the automated process results in a homogenous distribution of stem and progenitor cells. However, our findings show that the clonogenic capacity differs between the two segments.
© 2012 The Authors. Transfusion Medicine © 2012 British Blood Transfusion Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23025789     DOI: 10.1111/j.1365-3148.2012.01191.x

Source DB:  PubMed          Journal:  Transfus Med        ISSN: 0958-7578            Impact factor:   2.019


  1 in total

1.  Detecting primitive hematopoietic stem cells in total nucleated and mononuclear cell fractions from umbilical cord blood segments and units.

Authors:  John Patterson; Cally H Moore; Emily Palser; Jason C Hearn; Daniela Dumitru; Holli A Harper; Ivan N Rich
Journal:  J Transl Med       Date:  2015-03-18       Impact factor: 5.531

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.